3PO1 image
Deposition Date 2010-11-21
Release Date 2011-11-23
Last Version Date 2024-11-20
Entry Detail
PDB ID:
3PO1
Title:
Thrombin in complex with Benzothiazole Guanidine
Biological Source:
Source Organism(s):
Homo sapiens (Taxon ID: 9606)
Method Details:
Experimental Method:
Resolution:
1.65 Å
R-Value Free:
0.26
R-Value Work:
0.22
R-Value Observed:
0.22
Space Group:
C 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Thrombin light chain
Gene (Uniprot):F2
Chain IDs:A
Chain Length:27
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Thrombin heavy chain
Gene (Uniprot):F2
Chain IDs:B
Chain Length:147
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Thrombin heavy chain
Gene (Uniprot):F2
Chain IDs:C
Chain Length:102
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:thrombin peptide
Chain IDs:D
Chain Length:10
Number of Molecules:1
Biological Source:Homo sapiens
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
TYS D TYR O-SULFO-L-TYROSINE
Primary Citation
Discovery of benzothiazole guanidines as novel inhibitors of thrombin and trypsin IV.
Bioorg. Med. Chem. Lett. 22 4839 4843 (2012)
PMID: 22726924 DOI: 10.1016/j.bmcl.2012.05.046

Abstact

In a project to find novel neutral P1 fragments for the synthesis of thrombin inhibitors with improved pharmacokinetic properties, fragments containing a benzothiazole guanidine scaffold were identified as weak thrombin inhibitors. WaterLOGSY (Water-Ligand Observed via Gradient SpectroscopY) NMR was used to detect fragments binding to thrombin and these fragments were followed up by Biacore A100 affinity measurements and enzyme assays. A crystal structure of the most potent compound with thrombin was obtained and revealed an unexpected binding mode as well as the key interactions of the fragment with the protein. Based on these results, the structure-based design and synthesis of a small series of optimized novel substituted benzothiazole guanidines with comparatively low pK(a) values was accomplished. Testing of these compounds against human trypsin I and human trypsin IV revealed unexpected inhibitory activity and selectivity of some of the compounds, making them attractive starting points for selective trypsin inhibitors.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
Feedback Form
Name
Email
Institute
Feedback